Automation of UBC® in China
AroCell announces today that the company has signed a new development agreement with ZECEN Biotech regarding the automation of one more of the company's tumor markers on ZECEN Biotech's automated platforms.
AroCell has collaborated with ZECEN Biotech since 2019 for the development of TPS CLIA on ZECEN Biotech and Fosun's automated CLIA platforms. The inclusion of an additional marker, UBC on automated platforms is in line with the company's strategy and is set to open up new opportunities and further strengthen AroCell’s presence in the Chines market.
“The company's strategy is to get more tumor markers out on automated platforms. We are very happy to start another development project with ZECEN Biotech to include the tumor marker UBC® on their fully automated CLIA system,” says Marie Torstensson, Chief Market and Sales Officer Laboratory Test.
About UBC®
UBC® is a quantitative in vitro diagnostic test for the prognosis and monitoring of patients with bladder cancer. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. Elevated amounts of cytokeratin fragments are found in the urine of many individuals with bladder cancer, even in the early stages of the disease. UBC® is also available as a quantitative POC test.
About ZECEN Biotech
ZECEN Biotech Co., Ltd., is a Chinese company that mainly specializes in providing total chemiluminescence immunoassay solutions by developing, manufacturing, and marketing CLIA instruments and reagents. The company has research and development centers and a production base in Beijing, Shandong, and Jiangsu. ZECEN Biotech Co., Ltd., and cooperates with leading hospitals in China.